Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships TrialNet: collaboration agreement (Feb 2025) to evaluate rezpegaldesleukin in new-onset stage 3 type 1 diabetes; TrialNet conducts the study with funding from the National Institutes of Health
Indications
Moderate-to-severe atopic dermatitis(Phase 3)
Severe-to-very-severe alopecia areata(Phase 2)
New-onset stage 3 type 1 diabetes mellitus(Phase 2)
Status note First two registrational Phase 3 trials (ZENITH AD-1 and ZENITH AD-2) in moderate-to-severe atopic dermatitis initiated Jul 2026. Phase 2b REZOLVE-AD completed; results announced Jun 2025. Topline results from the Phase 2b REZOLVE-AA alopecia areata study announced Dec 16, 2025. Phase 2 study in new-onset stage 3 type 1 diabetes with TrialNet initiated May 2026.
NKTR-0165
Preclinical · ActiveModality: antibody
Target tumor necrosis factor (TNF) receptor type II (TNFR2)
Partnerships Biolojic Design, Ltd.: exclusive license (option exercised Dec 2023) to specified agonistic antibodies and other materials for TNFR2 agonism program; up to $18.0M in potential milestones
Indications
Autoimmune diseases(Preclinical)
Status note Preclinical TNFR2 agonist asset; lead research program.
NKTR-0166
Preclinical · ActiveModality: antibody
Target tumor necrosis factor (TNF) receptor type II (TNFR2)
Partnerships Biolojic Design, Ltd.: exclusive license (option exercised Dec 2023) to specified agonistic antibodies and other materials for TNFR2 agonism program; up to $18.0M in potential milestones
Indications
Autoimmune diseases(Preclinical)
Status note Preclinical TNFR2 agonist asset.
NKTR-255
Stage not disclosed · ActiveModality: investigational biologic
Target interleukin-15 (IL-15) pathway
Indications
Oncology(Stage not disclosed)
Status note Investigational biologic in oncology. Nektar is seeking partnerships for this asset.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Grade 3b Follicular Lymphoma
—
Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 3 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.